Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human astrocytoma cells by the pyrrolo-1,5-benzoxazepine, PBOX-21

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1639, Issue 1, 2003, Pages 43-52

  Mulligan, Jude M ^a   Campiani, Giuseppe ^b   Ramunno, Anna ^b   Nacci, Vito ^b   Zisterer, Daniela M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

1321N1; Cell cycle; Cyclin dependent kinase; G1 arrest; Pyrrolo 1,5 benzoxazepine

Indexed keywords

CYCLIN D3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; OXAZEPINE DERIVATIVE; PHOSPHOTRANSFERASE; PROTEIN P21; PYRROLO 1,5 BENZOXAZEPINE; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; COMPLEX FORMATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GROWTH INHIBITION; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0041474827     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(03)00128-5     Document Type: Article

References (9)

1. Zisterer D.M., Hance N., Campiani G., Garofalo A., Nacci V., Williams D.C. Antiproliferative action of pyrrolobenzoxazepine derivatives in cultured cells: absence of correlation with binding to the peripheral-type benzodiazepine binding site. Biochem. Pharmacol. 55(4):1998;397-403.
2. Schrijvers D., Vermorken J.B. Update on the taxoids and other new agents in head and neck cancer therapy. Curr. Opin. Oncol. 10(3):1998;233-241.
3. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Prog. Cell Cycle Res. 1:1995;351-363.
4. McDonald E.R. III, El-Deiry W.S. Checkpoint genes in cancer. Ann. Med. 33(2):2001;113-122.
5. Campiani G., Nacci V., Fiorini I., De Filippis M.P., Garofalo A., Ciani S.M., Greco G., Novellino E., Williams D.C., Zisterer D.M., Woods M.J., Mihai C., Manzoni C., Mennini T. Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligands. J. Med. Chem. 39(18):1996;3435-3450.
6. Sladowski D., Steer S.J., Clothier R.H., Balls M. An improved MTT assay. J. Immunol. Methods. 157(1-2):1993;203-207.
7. Murai T., Nakagawa Y., Maeda H., Terada K. Altered regulation of cell cycle machinery involved in interleukin-1-induced G(1) and G(2) phase growth arrest of A375S2 human melanoma cells. J. Biol. Chem. 276(9):2001;6797-6806.
8. McGee M., Campiani G., Ramunno A., Nacci V., Lawler M., Williams D.C., Zisterer D.M. Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells. J. Biol. Chem. 277(21):2002;18383-18389.
9. 1 phosphorylation on threonine-26 prevents its praid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11(8):1997;957-972.